Iconovo AB

Equities

ICO

SE0010868943

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 08:14:39 03/06/2024 pm IST			5-day change	1st Jan Change
11.15 ^SEK	-7.47%		+0.45%	-3.46%

15/05	Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments	CI
06/05	Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler	MT

BioStock: Busy days for Iconovo at BIO-Europe

November 20, 2023 at 02:29 pm IST

Iconovo had three hectic days at BIO-Europe, with a large number of meetings booked with potential partners. The company especially highlighted their latest innovation, ICOone Nasal, enabling inhalation through the nasal cavities. BioStock reached out to Fredrik Radencrantz, the company's Director Business Development, to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/11/busy-days-for-iconovo-at-bio-europe/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/iconovo/r/biostock--busy-days-for-iconovo-at-bio-europe,c3878862

Latest news about Iconovo AB

Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments	15/05	CI
Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler	06/05	MT
Iconovo AB Receives Patent Protection for Icores in China	06/05	CI
Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone	11/03	CI
Iconovo AB Reports Earnings Results for the Full Year Ended December 31, 2023	16/02	CI
Iconovo AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	16/02	CI
Iconovo AB Signs Additional Contract with Kiox Pharma for the Development of A New Inhalable Treatment for Interstitial Lung Disease	07/02	CI
Iconovo AB Launches Improved Versions of Nasal ICOone Inhalers	06/02	CI
Iconovo Receives Order from Top-10 Pharma Company for Evaluation of Multi-Dose Inhaler	01/02	CI
Arcede Pharma and Iconovo AB Takes the Next Step in the Development of a New Treatment for COPD	16/11	CI
Iconovo AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/23/27	CI
Iconovo AB Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone	26/23/26	CI
Iconovo AB Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations	19/23/19	CI
Iconovo AB Launches Outreach Phase in Structured Process for Out-Licensing of ICOpre	13/23/13	CI
Iconovo AB Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027	23/23/23	CI
Iconovo to Launch Pharmacokinetic Study for Inhalable Treatment Under Kiox Pharma Partnership	17/23/17	MT
Iconovo AB Receives Additional Development Contract from Kiox Pharma for New Inhalable Treatment Against Rare Disease	17/23/17	CI
Iconovo AB, Provides Earnings Guidance for 2024 and 2025	16/23/16	CI
Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Iconovo Increases Sales Efforts and Supply Chain Security for ICOcap Through Restructured Agreement with Stevanato	13/23/13	CI
Iconovo Initiates Collaboration with Affilogic	22/23/22	CI
Sweden's Iconovo to Conduct Feasibility Study on New Treatment of Rare Disease	09/23/09	MT
Iconovo AB Strengthens its Customer Offering in the Novel Pharmaceuticals Business Segment	01/23/01	CI
Iconovo AB Announces Appoints Carl Lindgren as Chief Business Development Officer	23/23/23	CI

Chart Iconovo AB

Duration

Period

More charts

Company Profile

Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Companyâs device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.

Sector

Medical Equipment, Supplies & Distribution

Calendar

12/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Iconovo AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Supplies

	1st Jan change	Capi.
ICONOVO AB	-3.46%	1.82Cr
COLOPLAST A/S	+4.53%	2.7TCr
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	-40.08%	266.52Cr
WINNER MEDICAL CO., LTD.	-21.07%	240.44Cr
HARTALEGA HOLDINGS	+16.30%	227.7Cr
INTCO MEDICAL TECHNOLOGY CO., LTD.	+8.60%	224.19Cr
HARBIN FUERJIA TECHNOLOGY CO., LTD.	-13.37%	182.47Cr
GVS S.P.A.	+24.48%	125.65Cr
NAKANISHI INC.	-1.10%	120.65Cr
KOSSAN RUBBER INDUSTRIES	+20.00%	120.34Cr

Medical Supplies